ID	Previously reported in Br J Psych	Infection History	Antiepileptic	Metformin	Oral prednisolone	Secondary diagnosis of malignancy	Recurrent infections (4 or more ABX oral per year, or >1 infection-related admission)	First Seen	Age at referral	Clozapine Duration/ years	Stopped Clozapine?	Calculated Globulin	IgG g/L	IgA g/L	IgM g/L	Hib IgG baseline	Tetanus IgG baseline	Pneumococcus IgG baseline	Vaccine details	Hib IgG Post vaccination	Tetanus IgG Post vaccination	Pneumococcus IgG Post vaccination	Neutrophils	Lymphocytes	CD3+ T	CD4+ T	CD8+ T	CD19+ B	CD16+	Naïve (%RL	Maximal Zone (%RL	CD45RA (%RL	CD45 bra (%RL	Transitional (%RL	Rheumatoid% (%RL	Antibiotics	Comment on IgMT
1	N	Recurrent respiratory tract infections (12 per year). Has also required chest drain insertions for loculated effusions	Y- Valproate	Y	N	N	Y	2007	37	Unclear; > 4	N	14	1.38	0.22	0.17	0.11	0.06	1.33	Menitorix and Pneumovax II	0.15	0.21	1.3	5	2	870	650	190	260	90	85.3	9.5	0.3	2	2	0	Prophylaxis	Y
2	N	Persistent cough for over a year and remains productive of green sputum despite several courses of antibiotics. Sputum sensitive HINF	N	N	N	N	Y	2013	63	7.5	Y- Ceased due to neutropenia	19	2.98	0.22	0.23	0.84	0.17	36	Menitorix and Pneumovax II	9	0.41	84	3.4	0.8	620	310	60	150	30	81.7	12.5	0.7	not performed	not performed	not performed	Prophylaxis	Y
3	N	Assessment for hypogammaglobulinaemia. Investigations including bone marrow examination have not revealed a clonal cause for this. 3-4 respiratory tract infections in the last year requiring antibiotics for 7 days. Prednisolone 40mg daily for 7 days with intermittent sinus tibicione	N	N	Y	N	Y	2016	46	21	N	14	3.4	0.27	0.18	0.44	1.62	4.34	Menitorix and Pneumovax II	1.93	6.05	7.85	6.3	2.1	1070	560	460	290	70	83.32	12.43	0.84	not performed	not performed	0	Prophylaxis	Y
4	N	2 years post starting clozapine: recurrent chest infections. Has had 2 previous admissions with pneumonia and 2 admissions with cellulitis. Most recent admission was to intensive care for 6 weeks.	Y- Valproate	N	N	N	Y	2014	49	7	N	15	1.2	0.01	0.07	0.11	0.05	3	Menitorix and Pneumovax II	0.23	0.1	3	7	1.9	930	490	440	370	220	86.2	14.4	0.2	1.54	1.74	0	Prophylaxis	Y
5	Y	Over the past 12 months with 7 courses of antibiotics for chest infections and 9 visits to his GP.	N	Y	N	N	Y	2016	59	10	N	14	2.38	0.22	0.17	2.19	0.07	11.06	Pneumovax II	2.21	0.68	13.73	4.2	1.3	650	680	160	140	50	56.22	32.41	3.17	not performed	not performed	0.02	Prophylaxis	Y
6	N	Respiratory tract infections and colds almost continuously for at least 5 years. In the past year 8 courses of antibiotics and been seen by GP on 7-8 occasions. 1 admission with pneumonia	N	N	N	Diagnosis of non-Hodgkin's lymphoma	Y	2013	57	>6	N	19	1.38	0.22	0.17	1.37	1.84	3	Menitorix and Pneumovax II	1.37	1.84	3	4.1	0.8	380	240	120	160	80	23.4	71.2	0.7	not performed	not performed	0.04 not performed	Prophylaxis	Y
7	N	1-2 possible chest infections during the winter and requiring up to a single course of antibiotics per year. This situation however worsened this year and since October required 6 courses of antibiotics for an almost constant cough.	N	N	N	N	Y	2014	63	10	Y- stopped since referred. Off Clozapine since the 22nd January 2015.	18	3.2	0.26	0.41	0.11	Not performed	3.3	Menitorix and Pneumovax II	9	7	80	2	1.2	940	650	180	170	130	64.38	31.57	1.58	not performed	not performed	not performed	Prophylaxis	N
8	N	Recurrent ear infections for the past 4 years and estimates over 10 courses of antibiotics per year	N	Y	N	N	Y	2018	47	unclear	N	21	3.16	0.73	0.17	0.11	0.77	7.85	Menitorix and Pneumovax II	0.87	7	51	4.4	1.1	1350	930	490	300	20	94.07	5.87	0.74	not performed	not performed	not performed	Prophylaxis	N
9	N	Chesty but no antibiotic courses	N	N	N	N	N	2012	51	5	N	21	2.68	0.38	0.17	0.11	0.39	5	Menitorix and Pneumovax II	0.18	1.24	4	6.8	1.3	910	600	310	140	80	69.1	21.2	5.5	12.1	8.8	0	Breakthrough	N
11	N	No antibiotics in the last 12 months and has had a single cold	N	N	N	N	N	2016	51	11	N	17	5.61	0.81	0.18	2.94	7	23.04	Pneumovax II	not performed	not performed	24.2	10.2	1	750	560	180	300	180	89.5	6.58	2.24	not performed	not performed	not performed	Breakthrough	N
15	N	Pneumonia and ITU admission, recent episode of jaundice	N	Y	N	N	N	2017	46	15	N	18	4	0.26	0.38	0.12	2.86	5.82	Pneumovax II	1.38	7	67.69	3.7	1.6	1960	1350	560	450	170	97.66	8.75	0.18	1.87	2.02	0.01	Breakthrough	N
16	N	Two respiratory tract infections in the last twelve months	N	N	N	N	N	2018	58	27	N	18	2.17	0.26	0.05	0.11	0.01	3.3	Under assessment	-	-	-	6	2	1640	1340	300	380	130	85.88	7.46	1.74	not performed	not performed	not performed	Breakthrough	N
17	N	They have not required antibiotics or had infections in the past year. (Low CG with immunoglobulins subsequently revoked to be borderline low)	N	N	N	N	N	2018	50	10	N	18	6	0.2	0.48	1.32	0.42	18.19	Pneumovax II	Under assessment			270	4	0.9	470	350	70	210	100	95.84	3.08	0.47	not performed	not performed	not performed	Breakthrough	N
Laboratory Reference Range (5–95th percentile unless otherwise stated)												22–63 g/L	6 to 16 a/L	0.80–4.00 a/L	0.50–2.00 a/L					>1.0 mca/ml	≥0.1 IU/ml	≥10mg/L	1.7–7.1 x10^9	1.0–4.5 x10^9/L	800–2100	400–1300	200–1100	12.0–22.0	80–610	59–79.6%*	7.4–32.1*	7.1–21.4*	7.2–16.9*	0.6–3.4*	0.6–3.4*			

* represent interquartile ranges